# Lilly Says Retatrutide Reduced A1C and Produced Weight Loss in Phase 3 Trial

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/42630
Published: 2026-10-28T13:43:45.000Z
Updated: 2026-10-28T13:43:45.000Z
Section: Business

> The company said the treatment reduced A1C, a biomarker associated with diabetes, alongside weight loss.

Eli Lilly said Wednesday, Oct. 28, that retatrutide produced weight loss and reduced A1C in a Phase 3 trial.

A1C is a biomarker associated with diabetes.